Abstract: Methods for treating liver immune dysfunction in a subject are provided. The liver immune dysfunction may be induced by at least one tumor resulting from metastasis in the liver or at least one primary liver cancer. An exemplary method comprises administering to the subject a toll-like receptor 9 (TLR9) agonist, for example, a TLR 9 agonist having the structure: 5?-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3. The TLR9 agonist is administered to the liver, for example, the TLR9 agonist may be administered to the liver using a locoregional therapy through the vasculature.

Abstract: The present disclosure relates to methods and formulations for treating respiratory viral infections by administering a statin by inhalation.

Abstract: present disclosure relates to methods for relaxing airway smooth muscle tissue, alleviating or preventing bronchospasm, and treating lung diseases by administering an HMG-CoA reductase inhibitor (statin) directly to lung tissue by inhalation. The disclosure also relates to formulations and compositions useful for the practice of methods of the disclosure.